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ABSTRACT
Background. Atherosclerosis progression is accelerated in
diabetes mellitus (DM) by either direct endothelial damage
or reduced availability and function of endothelial progen-
itor cells (EPCs). Both alterations are related to increased
oxidant damage.
Aim. We examined if DM specifically impairs vascular
signaling, thereby reducing the recruitment of normal
EPCs, and if increases in antioxidant levels by induction of
heme oxygenase-1 (HO-1) can reverse this condition.
Methods. Control and diabetic rats were treated with the
HO-1 inducer cobalt protoporphyrin (CoPP) once a week
for 3 weeks. Eight weeks after the development of diabetes,
EPCs harvested from the aorta of syngenic inbred normal
rats and labeled with technetium-99m-exametazime were
infused via the femoral vein to estimate their blood clear-
ance and aortic recruitment. Circulating endothelial cells
(CECs) and the aortic expression of thrombomodulin (TM),
CD31, and endothelial nitric oxide synthase (eNOS) were
used to measure endothelial damage.
Results. DM reduced blood clearance and aortic recruit-
ment of EPCs. Both parameters were returned to control
levels by CoPP treatment without affecting EPC kinetics in
normal animals. These abnormalities of EPCs in DM were
paralleled by reduced serum adiponectin levels, increased
numbers of CECs, reduced endothelial expression of phos-
phorylated eNOS, and reduced levels of TM, CD31, and
phosphorylated AMP-activated protein kinase (pAMPK).
CoPP treatment restored all of these parameters to normal
levels.
Conclusion. Type II DM and its related oxidant damage
hamper the interaction between the vascular wall and nor-
mal EPCs by mechanisms that are, at least partially, re-
versed by the induction of HO-1 gene expression, adiponec-
tin, and pAMPK levels. STEM CELLS 2009;27:399–407
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INTRODUCTION
Vascular disease is the principal cause of death and disability in
patients with diabetes mellitus (DM). The accelerated progres-
sion of diabetic atherosclerosis is attributed to the imbalance
between increased endothelial injuries and hampered endothe-
lial repair processes [1]. The relevance and the mechanisms of
the endothelial damage in DM are characterized by an abnormal
control of vasomotor tone associated with an accelerated rate of
cell apoptosis and sloughing [2, 3]. More recently, numerous
studies—focused on the alterations induced by DM on the
function of circulating endothelial progenitor cells (EPCs)—
demonstrated that DM impairs EPC migration [4, 5], their
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adhesive properties [6], as well as their capacity to proliferate
[7, 8], to incorporate into vascular structures, and to contrib-
ute to vasculogenesis in the ischemic tissues of nondiabetic
models [9].
Interestingly, both disorders—accelerated vascular damage
and impaired EPC biology—reflect similar molecular alter-
ations partially related to the overproduction of reactive oxygen
species (ROS) [5, 10, 11]. Increased ROS levels are a well-
documented mechanism of endothelial injury and a potent stim-
ulus for the production of proinflammatory atherogenic cyto-
kines; however, they also affect EPC mobilization, function, and
survival either directly [12, 13] or via a reduction in endothelial
nitric oxide synthase (eNOS) activity and nitric oxide (NO)
bioavailability [12, 14]. Similarly, interventions able to poten-
tiate tissue antioxidant power have been proven to provide a
simultaneous benefit to vascular integrity and stem cell biology.
In fact, upregulation of heme oxygenase-1 (HO-1) gene expres-
sion has been found to increase vascular repair processes [15,
16], to improve NO-dependent vasomotor control [17], to down-
regulate the production of interleukin-6 and tumor necrosis
factor (TNF)- [18, 19], and, finally, to reduce the evidence of
cell sloughing, apoptosis, and death [2, 15]. On the other hand,
this same intervention has been found to improve stem cell
biology [20] via a reduction in ROS production by adipocytes,
resulting in increased levels of serum adiponectin [18, 21, 22].
Indeed, reductions in circulating adiponectin have been consis-
tently associated with obesity, insulin resistance, type 2 DM,
and coronary artery disease [23, 24], whereas recent data have
revealed that adiponectin plays a vascular protective role by
preserving endothelial cell function in diabetic patients [25].
We have reported that enhanced vascular HO-1 expression
increases serum adiponectin and enhances the concentration
of phosphorylated phosphatidylinositol 3-kinase (pAKT) [17,
26]. Moreover, a large body of evidence has shown that
adiponectin-mediated activation of AMP-activated protein
kinase (AMPK) and pAKT increases the phosphorylation of
a number of target molecules, resulting in increased glucose
transport, fatty acid oxidation [19, 25], and phosphorylated
eNOS (peNOS) [12] and an improvement in cell survival [12]
and protection against oxidative stress [26–29]. Thus, in-
creased oxidant damage may specifically hamper the capa-
bility of the diabetic vascular wall to recruit EPCs regardless
of the availability and the function of these “spare parts.”
Should this hypothesis be confirmed, it would provide a
better understanding of the accelerated progression of ath-
erosclerosis in diabetic patients. In addition, the identifica-
tion of this effect could provide new insights into the im-
provement in stem cell-based treatments. However, despite
these critical mechanistic and physiological implications, this
hypothesis has never been directly tested.
Accordingly, the objective of this study was to examine
whether DM specifically impairs the recruitment of EPCs, using
radioactive labeling that allows detection of the presence of
small numbers of EPCs in vascular structures and in different
organs. To verify the role of oxidant damage in this process, we
examined whether blood kinetics and vascular recruitment of
normal EPCs were paralleled by ROS-dependent vascular dam-
age in a rat model of streptozotocin (STZ) type 2 DM. More-
over, to define the mechanisms underlying these alterations, we
tested the response of these indices in a phenotype precondi-
tioned by the upregulation of HO-1 and endothelium protective
signaling proteins by treatment with cobalt protoporphyrin
(CoPP).
MATERIALS AND METHODS
Animal Models
All experiments were approved by the Institutional Animal Care
and Use Committee of the University of Genoa and Pisa and
conducted under the guidelines for the Care and Use of Laboratory
Animals, published by the Office of Science and Health Reports,
National Institutes of Health. In total, 24 male Sprague Dawley rats,
8–12 weeks of age, were included in the study: seven control rats,
seven diabetic rats, five control rats treated with CoPP, and five
diabetic rats treated with CoPP. Type 2 mild and stable diabetes
with reduced -cell mass was induced by i.p. administration of 210
mg/kg of nicotinamide dissolved in saline (Sigma-Aldrich, St.
Louis, http://www.sigmaaldrich.com) 15 minutes before an i.p. in-
jection of STZ, 60 mg/kg (Sigma), dissolved in citrate buffer (pH
4.5) immediately before use [30]. This procedure provides a model
for noninsulin-dependent DM syndrome and is regarded as similar
to human type 2 diabetes in that it has a significant insulin respon-
siveness to glucose and preserved sensitivity to tolbutamide due to
partial pancreatic protection by nicotinamide [30]. CoPP (0.5 mg/
100 g body weight) was administered s.c. once a week for 3 weeks
after STZ.
EPC Harvesting, Expansion, and Labeling
Aortas from 8-week-old Sprague Dawley rats were explanted and
treated as follows for the isolation of EPCs. Tissues pieces were
washed in phosphate-buffered saline (PBS), mechanically minced,
and enzymatically digested after incubation for 10 minutes at 37°C
in digestion solution constituted by 1 trypsin. After filtration and
removal of undigested tissue, cells were washed in PBS and cen-
trifuged for 10 minutes at 250g. Cells were then resuspended in
endothelial medium (EGM2) and plated in collagen-coated six-well
plates at a density of 5  10
6 cells/well. Fresh medium was added
48 hours later and was replaced twice a week. In the present study,
we used cells cultured for up to four passages. The lack of hema-
topoietic contaminants was tested via fluorescence-activated cell
sorting and was negative for CD45. The endothelial nature of these
cells was confirmed by the homogeneous expression of CD31,
CD144, and von Willebrand factor (vWF), thus excluding contam-
ination of mural or muscle-derived cells (data not shown).
Labeling was performed by incubating 2  10
6 cultured cells
with technetium (Tc)-99m-exametazime (HMPAO, Ceretec; GE
Healthcare, Milwaukee, WI, http://www.gehealthcare.com) accord-
ing to a procedure described in the literature [31] and modified and
validated in our laboratory. Briefly, EPCs in suspension were incu-
bated for 30 minutes at 37°C in a solution containing 3.7 MBq of
Tc-99m-HMPAO. After two to three PBS washes, the cells were
centrifuged and resuspended in 1 ml of saline and subdivided into
three aliquots after removal of the supernatant: 2  450 l for
injection into two different animals and 100 l for the estimation of
the injected dose. Labeling yield, defined as cell count/(cell count 
supernatant count), was in the range of 39%–43% (41%  1%).
Labeling stability was estimated in a total of eight experiments in
which cells were reattached and maintained at 37°C for 24 hours in
an atmosphere containing 5% CO2. EPCs were then resuspended
and centrifuged before counting. The decay-corrected radioactivity
at 24 hours was in the range of 93%–96% of that documented soon
after labeling. Similarly, the trypan blue exclusion test was used to
determine preserved viability in all cultures.
Experimental Protocol
After treatment with saline or STZ, all animals were housed for 2
months and given food and water ad libitum. Blood samples were
collected weekly from the tail vein following a 4-hour fasting period
in order to measure glucose levels by the glucose oxidase method
(Glucocard GT-1610; Menarini Diagnostic, Firenze, Italia, http://
www.menarini.com). The animals were then anesthetized with pen-
tobarbital sodium (40 mg/kg) and a jugular vein was exposed for
cannulation. Thereafter, labeled EPCs (10
6, with a mean activity of
18.5 kBq) were infused via a femoral vein. Blood samples (100 l)
were obtained from the jugular vein catheter at 15, 30, 45, 60, 75,
400 Vascular Repair and Adiponectin/pAMPK90,120, 150, 180, and 240 minutes after cell injection and stored in
preweighed vials containing 5 l of heparin. In all cases, the
catheter was washed with a corresponding volume of heparinated
saline. All procedures were performed using Hamilton syringes
(LaboIndustria SpA, Padoa, Italy, http://www.laboindustria.com).
At the end of the study period, all animals were sacrificed and the
following organs were harvested: lungs, spleen, liver, heart, and
aorta. All blood samples were weighed with a precision balance and
centrifuged for 5 minutes at 3,000 rpm to remove serum. Radioac-
tivity of the centrifuged samples was measured in a gamma counter
and results are expressed as a percentage of dose per ml of blood,
considering a blood density of 1.05 g/ml. Blood clearance of labeled
injected EPCs was evaluated by the hourly decrease in radioactivity
concentration in the blood. Organ radioactivity was expressed as a
percentage of the injected dose.
Analysis of Blood Variables
Before labeled cell injection, 2-ml blood samples were obtained for
subsequent analysis. Serum adiponectin (high molecular weight)
was determined using an enzyme-linked immunosorbent assay
(ELISA) (Pierce Biotechnology, Inc., Woburn, MA, Rockford, IL,
http://www.piercenet.com). Insulin levels were determined by an
ELISA method (Mercodia, Uppsala, Sweden, http://www.mercodia.
com). Detection and quantification of circulating endothelial cells
(CECs) were performed using monodispersed magnetizable parti-
cles (Dynabeads CELLection Pan Mouse IgG kit) obtained from
Invitrogen (Carlsbad, CA, http://www.invitrogen.com). Typically,
100 l of bead suspension was noncovalently coated with 10 g/ml
of RECA-1 (Novus Biologicals, Littleton, CO, http://www.
novusbio.com), a panrat endothelial cell-specific monoclonal anti-
body, and CECs were determined as previously described [2, 32].
Finally, the concentration of oxidized proteins was assayed using
ELISA kits (Cayman Chemical Co, Ann Arbor, MI, http://www.
caymanchem.com).
Western Blot Analysis of Aortas for HO, eNOS,
AMPK, pAMPK, AKT, and pAKT
Frozen aortas were pulverized under liquid nitrogen and placed in a
homogenization buffer (10 mmol/l phosphate buffer, 250 mmol/l
sucrose, 1 mmol/l EDTA, 0.1 mmol/l phenylmethylsulfonyl fluoride
(PMSF), and 0.1% vol/voltergitol, pH 7.5). Homogenates were
centrifuged at 27,000g for 10 minutes at 4°C, the supernatant was
isolated, and protein levels were visualized by immunoblotting with
antibodies against HO-1 and HO-2 (Stressgen Biotechnologies
Corp., Victoria, BC, Canada, http://www.stressgen.com). Antibod-
ies against AKT, AMPK, pAMPK, and pAKT were obtained from
Cell Signaling Technology, Inc. (Beverly, MA, http://www.
cellsignal.com), eNOS was from Santa Cruz Biotechnology Inc.
(Santa Cruz, CA, http://www.scbt.com), and 3-NT was from Up-
state cell signaling solutions (Chicago, IL, http://www.upstate.com).
Antibodies were prepared at the following dilutions: HO-1 and
HO-2, 1:1,000; 3-NT, 1:1,000; eNOS, pAMPK, and pAKT, 1:5,000
and 1:1,000 for the cellular apoptotic mediators.
Briefly, 20 g of aortic tissue lysate supernatant was separated
by 12% SDS-PAGE and transferred to a nitrocellulose membrane.
Immunoblotting was performed as previously described [17].
Chemiluminescence detection was performed with the Amersham
ECL detection kit (Amersham, Piscataway, NJ, http://www.
amersham.com), according to the manufacturer’s instructions.
Immunohistochemical Staining
Thrombomodulin (TM) and CD31 were determined immunohisto-
chemically as previously described (TM [33], CD31 [16]).
Determination of HO Activity
Frozen aortas were pulverized under liquid nitrogen and placed in
homogenization buffer (10 mmol/l phosphate buffer, 250 mmol/l
sucrose, 1 mmol/l EDTA, 0.1 mmol/l PMSF, and 0.1% vol/volter-
gitol, pH 7.5). Homogenates were centrifuged at 27,000g for 10
minutes at 4°C. HO activity was determined and expressed as
bilirubin formation per mg protein/hour, as previously described
[26] using an Extinction Coefficient of 40 mM
1cm
1.
Statistical Analyses
Data are presented as the mean  standard error for the number of
experiments. Statistical significance (p  .05) between experimen-
tal groups was determined by the Fisher method of analysis of
multiple comparisons. For comparison between treatment groups,
the null hypothesis was tested by a single-factor analysis of variance
for multiple groups or an unpaired t-test for two groups.
RESULTS
Effect of CoPP on Body Weight, Plasma Glucose,
and Plasma Insulin
Animals treated with STZ exhibited diabetes that was confirmed
by significantly (p  .05) elevated levels of plasma glucose
compared with control animals. Plasma insulin and body weight
were unaffected by STZ treatment. CoPP treatment had no
effect on these variables in both diabetic and nondiabetic ani-
mals (Table 1).
Kinetics and Homing of EPCs
As displayed in Figure 1A, the persistence of EPCs in blood was
longer in diabetic than in control rats, as seen by a higher
concentration of EPCs in the blood of control compared with
diabetic animals (p  .01) throughout the study period. CoPP
treatment reduced the blood concentration of labeled EPCs (p 
.01) in diabetic animals to values close to those in control
animals, while producing no significant effect on normal rats.
The disappearance rate of EPCs from blood confirmed this
concept: the blood concentration of injected EPCs decreased
every hour by 8%  1% in diabetic animals and by 25%  2%
in control animals (p  .01). Treatment with CoPP increased the
blood clearance of EPCs in diabetic animals (to 20%  2%; p 
.01 versus diabetes without CoPP, not significant versus control)
but not in naive animals (to 19%  1%, not significant versus
control) over the first hour, and it remained greater than in
diabetic animals throughout the period of study (Fig. 1B). The
abnormally low blood clearance of EPCs in diabetic animals
was paralleled by a reduction in vascular recruitment of these
cells, as shown by lower aortic uptake in diabetic versus control
animals (0.01%  0.001% versus 0.04%  0.001% of injected
Table 1. General features of the experimental models
Control (n  7) Diabetes (n  7)
Control  CoPP
(n  5)
Diabetes  CoPP
(n  5)
Body weight (g) 421  93 411  80 297  77 411  10
Plasma glucose (mg/dl) 147  6.7 304  51
a,b 151  18 291  41
a,b
Plasma insulin 0.90  0.30 1.02  0.30 0.80  0.24 1.06  0.26
Values are the mean  standard error of the mean.
ap  .05 versus control;
bp  .05 versus control  CoPP.
Abbreviation: CoPP, cobalt protoporphyrin.
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cantly increased EPC recruitment in diabetic rats (to 0.03% 
0.001%; p  .01 versus nontreated diabetic rats) but not in naive
rats (0.03%  0.0005%, not significant versus control) (Fig.
2A). In contrast, the effect of long-lasting DM on lung seques-
tration of injected EPCs was the opposite: it was larger in
diabetic than in control animals (31%  1.5% versus 17% 
1.4%, respectively; p  .05). Again, CoPP treatment returned
lung uptake of EPCs to normal levels in diabetic animals (to
20%  1.5%; p  .05 versus nontreated diabetic animals) but
had no effect in naive rats (19%  1.5%%, not significant
versus controls) (Fig. 2B). Finally, neither diabetes nor CoPP
treatment affected EPC uptake in the spleen or liver (Fig. 2C,
D).
Effect of CoPP on Serum Oxidative Stress
Oxidized protein (carbonyl) content was elevated in diabetic rats
(1.75  0.42 nmol/mg) compared with controls (1.10  0.27
nmol/mg; p  .05) (Fig. 3A). CoPP treatments decreased serum
oxidative stress, as seen by a decrease in carbonyl content
(1.28  0.27 nmol/mg).
Effect of CoPP on HO Activity, Serum Adiponectin,
and Endothelial TM and CD31 Levels
As seen in Figure 3B, HO activity was reduced in diabetic rat
aortas and was increased by CoPP administration in aortas
isolated from diabetic rats (from 0.81 to 3.58 nmol/60 minutes
per mg protein) (Fig. 3B). This was associated with an increase
in HO-1 protein levels (results not shown). Similarly, diabetic
animals had decreased serum levels of adiponectin compared
with control animals. Again, CoPP treatment significantly in-
creased serum adiponectin levels in diabetic animals to levels
twofold higher than those found in control animals (Fig. 3C).
Immunohistochemical staining for TM was localized within the
endothelial cell cytoplasm. TM staining was strong in the intima
of control rats whereas diabetic rats demonstrated moderate to
weak staining (Fig. 4A). CoPP treatment restored TM expres-
sion in diabetic rats to the level of staining seen in aortas from
control animals (Fig. 4A). Optical density analysis of immu-
nohistochemical staining provided quantification of the
changes in TM expression. Similar results were seen for
CD31 (Fig. 4C, 4D).
Effect of CoPP on CEC Fragmentation
Using immunomagnetic isolation, we identified a well-defined
population of cells in the peripheral blood of normal and dia-
betic rats, which reproducibly stained positive for vWF, CD34,
and Ulex europaeus agglutinin-1. These CECs were larger than
other blood cells (10–50 m in length) and had an oval or round
shape (results not shown). Immunofluorescence staining was
computed as the integrated optical density and was measured in
four to seven samples for each experimental group. Figure 5A
shows that DM was associated with a marked increase in the
number of CECs (48  12 cells/ml versus 7  4 cells/ml,
respectively; p  .01). CoPP treatment significantly decreased
the number of CECs (23  5 cells/ml; p  .01 compared with
nontreated diabetic rats). Figure 5B displays the number of
endothelial cell membrane fragments, an indicator of cell apo-
ptosis. There was an 8- to 12-fold increase in cell fragmentation
in diabetic rats compared with controls (p  .001). HO-1
upregulation by CoPP diminished the number of fragments (p 
.001) compared with nontreated diabetic animals.
Effect of CoPP on eNOS and pAMPK
Finally, we verified if the restoration of TM and CD31 in the
aortas of diabetic rats was associated with increases in eNOS
protein levels. As seen in the Western blot analysis and densi-
tometry evaluation (Fig. 6A), CoPP administration to diabetic
rats resulted in a significant increase in eNOS protein (p  .05)
compared with untreated diabetic rats. Thus, the ability of HO-1
expression to augment vascular repair in vivo may be due, in
part, to an increase in the levels of eNOS.
As expected, induction of diabetes resulted in no significant
changes in AKT but significant decreases in both pAKT and
pAMPK. Upregulation of HO-1 by CoPP administration in-
creased the levels of both the pAKT and pAMPK proteins. As
seen on densitometry analysis, pAKT was significantly in-
creased in diabetic rats treated with CoPP, compared with non-
treated diabetic rats (p  .05). Similarly, a significant increase
in pAMPK was seen in diabetic rats treated with CoPP (p  .01)
(Fig. 6B) when compared with nontreated diabetic animals.
DISCUSSION
This study is the first in vivo characterization of the effects of
DM on the trafficking of normal EPCs. The data show that DM
markedly impairs the vascular recruitment of normal EPCs,
prolongs their residence in circulating blood, reduces their aortic
recruitment, and increases their lung sequestration. All these
abnormalities are corrected by induction of the HO-1 gene,
which, in contrast, does not affect EPC kinetics and distribution
Figure 1. EPC kinetics in blood. (A): Time concentration curves of
radioactivity in the blood are shown expressed as a percentage of the
dose (and thus, of the labeled injected EPCs). Diabetes was associated
with a prolonged persistence of EPCs in the blood, as seen by the higher
values of radioactivity (and thus, of EPC concentration) at each time
point. Induction of heme oxygenase-1 (HO-1) gene expression by CoPP
treatment (gray symbols) selectively accelerated EPC clearance from the
blood in diabetic animals (squares), without an effect on nondiabetic rats
(circles). (B): Whole body clearance of EPCs. Diabetes was associated
with a marked reduction in EPC recruitment in the body, expressed by
a prolonged persistence of these cells in the blood (**p  .01), whereas
CoPP treatment restored this variable to normal values. Abbreviations:
CoPP, cobalt protoporphyrin; EPC, endothelial progenitor cell.
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due to the antioxidant effect of HO-1 gene induction results in
the reprogramming of EPC signaling components, as manifested
by the restoration of the activities of pAMPK and peNOS and an
increase in vascular repair in diabetic animals. These data ex-
tend our knowledge on the interaction(s) between stem cells and
tissues under disease conditions and show that an elevated ROS
concentration specifically impairs signaling by the diabetic vas-
cular tree that is necessary to recruit even normal EPCs.
In the present study, we directly labeled EPCs with Tc-99m-
HMPAO using a method clinically validated to obtain radioac-
tive leukocytes and adapted to obtain stable binding throughout
the experiment without any significant effect on EPC viability
and function [34]. According to tracer kinetic theory, monitor-
ing radioactivity in blood cells and measuring its final uptake in
each organ estimates the number of cells cleared from the blood
per unit time and the number of cells recruited by each organ.
The loss of about 64% of the cells from the circulation in 4
Figure 2. EPC recruitment rate in the aorta, lung, spleen, and liver. The recruitment rate was unaffected by diabetes and CoPP treatment in the liver
and spleen. Reciprocal results are seen in the aorta and lung of diabetic animals. **p  .001, diabetic rats versus controls. Abbreviations: CoPP,
cobalt protoporphyrin; EPC, endothelial progenitor cell.
Figure 3. Molecular effects of CoPP treat-
ment. (A): Enzyme-linked immunosorbent
assay for the presence of serum oxidized
proteins. CoPP restored normal values of
oxidized proteins in the serum of diabetic
rats; n  5, *p  .01 versus control, **p 
.01 versus diabetes. (B): Heme-oxygenase
activity in the aorta, n  4. CoPP treatment
markedly increased Hemeoxygenase activity
in diabetic rats, **p  .001 versus control
and diabetic animals. (C): Adiponectin lev-
els in the plasma of control rats, diabetic
rats, and diabetic rats treated with CoPP.
CoPP markedly increased serum concentra-
tion of this hormone in diabetes: n  4. *p 
.05 control versus Diabetic and control rats.
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unexpectedly high rate process in normal animals and that the
time span of our study is large enough to detect a significant
impairment induced by DM. Similarly, the rapid nature of this
phenomenon accounts for the number of injected cells that
resulted in a concentration of EPCs in the first blood sample
well within the physiological range (0.16%–0.32% of the dose/
ml, or 16–32 EPCs/l) documented in clinical studies [34].
The decreased aortic recruitment contrasts with the in-
creased uptake of EPCs in diabetic lungs. Despite its paradox-
ical appearance, this difference is better understood when the
uptake mechanisms in the two structures are considered. The
aorta is exposed to laminar flow and no physical sequestration
of cells can occur. Accordingly, radioactivity (cell) uptake has
to be interpreted as the result of cell adhesion. In contrast, every
substance injected i.v. has to cross the pulmonary capillaries to
be available for distribution in the body and to be present in
circulating blood. Therefore, injection of particulate tracers can
result in pulmonary sequestration of those particles—cells—
that physically cannot cross tubes of 7 m in diameter. This
concept represents the basis of lung perfusion scintigraphy and
has been confirmed for i.v. injection of labeled mesenchymal
Figure 4. Immunohistochemical staining of TM (A) and CD31 (B) from control and diabetic animals. (C): Optical density analysis of TM staining
in diabetic rats and its restoration by CoPP. *p  .05, control versus diabetic animals, mean  standard error, n  40. Abbreviations: CoPP, cobalt
protoporphyrin; CTR, control; I, tunica intima; IOD, integrated optical density; M, tunica media; TM, thrombomodulin.
Figure 5. Reduction of endothelial damage
by CoPP treatment. (A): The number of
CECs increased significantly in STZ-in-
duced diabetic rats (p  .05) relative to
control rats. Administration of the heme ox-
ygenase-1 inducer CoPP decreased the num-
ber of CECs, n  6. *p  .05 versus con-
trols; #p  .05 versus diabetic rats. (B):
Similarly, endothelial cell membrane frag-
ments in blood obtained from control rats
were increased in diabetic rats and decreased
after CoPP treatment, n  5. *p  .001
versus controls; #p  .001 versus diabetic
rats. Abbreviations: CEC, circulating endo-
thelial cell; CoPP, cobalt protoporphyrin;
STZ, streptozotocin.
404 Vascular Repair and Adiponectin/pAMPKcells [31]. Accordingly, the increased sequestration of EPCs in
diabetic lungs is explained by the pulmonary microvascular
alterations reported in STZ-treated rats characterized by a high
prevalence of capillary collapse associated with focal thickening
of basal lamina in the capillary endothelium [35].
Regarding the aims of the present study, the large number of
cells sequestered in diabetic lungs has two important implica-
tions. First, it prevents the evaluation of EPC adhesion in the
pulmonary endothelium due to the large contamination of
wedged radioactive cells. Second, lung removal of labeled EPCs
from the circulation results in reduced numbers of circulating
EPCs in diabetic rats. Accordingly, the elevated concentration
of radioactivity in these animals indicates that the recruitment of
EPCs throughout the diabetic vascular system is even more
impaired than expected. This is confirmed by the effect of
CoPP, which selectively reversed EPC recruitment in the lung
and aorta of diabetic animals. Obviously, the kinetic character-
ization of EPCs collected from diabetic animals and injected
into nondiabetic animals may provide insights into vessel–EPC
signaling. However, the expansion of EPCs in vitro may reduce
the effect of the “diabetic memory” of injected cells, thus
hampering the interpretation of the data.
Together with the prolongation of EPC persistence in the
blood in DM and its response to CoPP, the reduced radioactivity
uptake in the aorta indicates that, besides damaging the mature
endothelium, elevated ROS concentrations also impair the re-
cruitment of EPCs by diabetic vessels. Therefore, these data
extend previous knowledge of the relationship between down-
regulation of HO-1 activity and accelerated progression of ath-
erosclerotic lesions in native vessels [36]. Similarly, they pro-
vide new insights into the mechanism underlying the beneficial
effect of HO-1-derived CO and bilirubin on endothelial cell
death and apoptosis both in vitro and in vivo [3, 19]. In fact, the
salutary effect of CoPP was confirmed by increased endothelial
levels of CD31 positivity and TM, whose downregulation is an
important index of endothelial cell death and progression of
atherosclerosis [13, 37]. In agreement with this concept, the
increased expression of CD31 and TM was associated with a
reduction in the number of CECs and cell fragments in CoPP-
treated diabetic animals, confirming the protective role of HO-1
induction and adiponectin on EPC recruitment by the diabetic
endothelium.
Endothelial cell dysfunction, demonstrated by the reduced
expression of CD31 [38, 39] and/or TM [37, 38], has been
reported within atherosclerotic blood vessels. A CD31 gene
Figure 6. Effect of CoPP treatment on en-
dothelial gene expression. (A): Western blot
and densitometry analysis of eNOS and pe-
NOS from control, diabetic, and CoPP-
treated diabetic rat aortas. Quantitative den-
sitometry evaluation of eNOS and peNOS in
the aorta was determined. Each bar repre-
sents the mean  standard error of four
experiments. *p  .001 for diabetic versus
CoPP-treated diabetic rats. (B): Effect of
diabetes and HO-1 expression on pAKT and
total AKT in the aorta’s proteins, and AMPK
and pAMPK. Quantitative densitometry
evaluations in aorta tissue homogenates of
pAKT and pAMPK are expressed as a ratio
to HO-2. *p  .01, diabetic rats versus con-
trol rats or CoPP-treated diabetic rats. Ab-
breviations: AKT, phosphatidylinositol 3-ki-
nase; AMPK, AMP-activated protein kinase;
CoPP, cobalt protoporphyrin; eNOS, endo-
thelial nitric oxide synthase; HO, heme ox-
ygenase; p, phosphorylated.
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atherosclerosis and myocardial infarction (MI) [40]. Further-
more, a reduction in plasma TM has also been associated with
an increased risk for MI [13]. Conversely, increased expression
of TM has been shown to limit thrombus formation as well as
neointimal growth [41]. The increase in TM and CD31 positiv-
ity limits neointimal formation and endothelial cell dysfunction
[38]. The diminished function of vascular endothelial cells
that occurs with diabetes [38, 41] is accompanied by a
reduction in EPC function [16, 42], which further impacts the
integrity of the intact endothelial lining. The increases in
pAMPK and pAKT induced by the chronic administration of
CoPP are likely major factors in EPC protection and an
indication of the restoration of vascular integrity. This is of
particular interest because reversal drugs, such as the statins,
known for their antiatherosclerotic properties, have been
shown to increase both HO-1 and eNOS.
The restoration of normal rates of EPC recruitment after
CoPP treatment was paralleled by increased levels of endothe-
lial pAMPK, eNOS, and peNOS. This latter observation seems
of particular relevance due to the pivotal role of reduced NO
bioavailability in the altered regulation of vasomotor tone, cell
adhesion, angiogenesis, and vasculogenesis that characterizes
the tissues of diabetic patients [43, 44]. This is further amplified
by the specific alteration in eNOS expression documented in the
bone marrow microenvironment, leading to reduced mobiliza-
tion of EPCs in DM [45].
The present data do not elucidate whether the reduced
expression of eNOS is the cause or the effect of the decreased
vascular recruitment of EPCs in DM. However, the relevance of
vessel stem cell interactions and their alterations provide a new
clue to understanding the effect of drugs, such as statins, known
for their antiatherosclerotic properties, and their ability to in-
crease both HO-1 [46] and eNOS [2, 47]. Similarly, the present
data do not permit us to conclusively identify the molecular
mechanism underlying the increased eNOS expression resulting
from upregulation of HO-1. However, at least two points must
be considered: first, CoPP treatment did not significantly de-
crease the severity of hyperglycemia in our animal model and
did not affect serum insulin levels; second, in contrast, circulat-
ing adiponectin levels were increased. This finding confirms
previous observations [18, 19] and seems of particular relevance
as adiponectin has been reported to possess a vascular protective
role [25], to preserve endothelial cell function in diabetic sub-
jects, to increase eNOS activity, and to reduce the expression of
eNOS inhibitors such as TNF- [48]. The association of in-
creased serum adiponectin levels and increased EPC recruitment
closely fits with previous findings by Ouchi et al. [49], who
reported a critical role for adiponectin in endothelial cell sur-
vival and function via the activation of eNOS, pAKT, and
pAMPK. These enzymes enhance peNOS levels [12, 50, 51],
suggesting that EPC recruitment is a result of the reprogram-
ming of specific metabolic pathways and their signaling com-
ponents, such as HO-1, pAMPK, and peNOS, in a manner that
enhances vascular repair.
CONCLUSIONS
The present data confirm the mechanisms underlying the endothe-
lial damage characteristic of DM and suggest that they also are
responsible for the impaired capability of the vascular wall to
recruit EPCs. The abnormal expression of eNOS, TM, and CD31
was associated with increased numbers of both CECs and cell
fragmentation, confirming the presence of structural endothelial
damage. Despite this evidence, we found that the capability to
recruit EPCs was reduced in diabetic vessels. Moreover, the ben-
eficial effect of HO-1 gene induction on the endothelial phenotype
was selectively observed in diabetic rats. Accordingly the selective
acceleration of EPC recruitment observed in these animals cannot
be ascribed to nonspecific vascular damage induced by CoPP
treatment and upregulation of HO-1 and the prevention of radical
generation. Rather, it strongly indicates that HO-1-preconditioned
endothelium is able to recruit more normal EPCs via an increase in
adiponectin and pAMPK. Accordingly, these results indicate that
the signaling disorder that interferes with the ability of the vascular
tree to recruit EPCs represents an important mechanism that un-
derlies the accelerated progression of atherosclerosis in DM. In
addition, it has the potential to amplify endothelial damage and to
reduce the number and the function of circulating EPCs observed in
these patients [52]. A deeper understanding of the mechanisms
involved will provide new approaches for the treatment of diabetic
atherosclerosis and improve the effectiveness of cell-based treat-
ment of vascular diseases.
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